Medscape Medical NewsAll articles

Oxehealth Vital Signs

Oxehealth Limited • Cardiovascular • 04/29/2022

510(k)IEC 62304 Class C
FDA Summary PDF

Device Purpose

The Oxehealth Vital Signs system utilizes optical video analysis via fixed cameras and proprietary software algorithms for the non-invasive spot-checking of adult pulse and breathing rates in non-critical healthcare settings. Its methodology relies on algorithmic interpretation of visual cues, primarily chest wall movements, with modifications in this version supporting expanded room coverage through multiple camera setups and an updated software stack including Python.

Summary

The Oxehealth Vital Signs device is a software system designed for non-invasive, spot-check measurements of pulse rate and estimated breathing rate derived from chest wall movements. It is intended for use on adult subjects (18 years or older) who are still, located in single occupancy rooms or designated single-occupancy areas within hospitals, general care facilities, and secured environments, specifically for individuals not requiring critical care or continuous vital signs monitoring; operation requires appropriately trained staff with professional healthcare oversight and its use is adjunctive, not the sole method for health assessment. The system processes video footage from fixed-installation, off-the-shelf cameras using custom-designed software with proprietary algorithms (employing C++, Python, and Node.js) to extract these physiological measurements. Performance validation has shown statistical non-inferiority compared to conventional methods, with pulse rate measurements between 50-130 bpm (±3 bpm) and breathing rate measurements between 8-31 breaths per minute (±2 bpm); this modified version maintains core functionality while allowing multiple camera setups to cover separate, non-overlapping areas within a larger room.

AI Regulatory Concerns

Powered byJev by TypeSafe AI

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

Keywords

Vital signsOptical cameraSoftware algorithmPulse rateBreathing rateNon-invasive measurementSpot check monitoringVideo analysis softwarePatient monitoringContactless sensing

Device Metadata

Submission Number
K220899
Company
Oxehealth Limited
Panel
Cardiovascular
Product Code
N/A
Data Type
Images
Clinical Function
Assessment
AI Function
Analysis
AI Subclass
quantification/feature localization

Relevant Clinical Questions

  • Q1. How does the system's performance vary with patient motion, different skin tones, or ambient lighting changes, and what are the defined operational thresholds for when the "subject is still"?; What specific image processing techniques and algorithms are employed to distinguish true physiological signals (pulse, respiration via chest wall movements) from noise and motion artifacts in diverse environmental conditions?; Considering the use of off-the-shelf cameras and potential deployment in "secured environments," what are the detailed cybersecurity measures, data encryption, and privacy protocols for the video data and derived vital signs?; How does the system manage scenarios where a patient is partially obscured by bedding or changes position frequently, particularly when monitoring separate, non-overlapping areas within a larger room using multiple camera installations?; What are the quantitative performance differences, if any, when using various compatible models of "off-the-shelf" cameras and computing hardware, and how is consistent measurement accuracy ensured across different installations and hardware configurations?

Risk Classification

ESL Analysis
FDA Device ClassII

FDA Class II via 510(k) pathway; IEC 62304 Class C (software safety classification); Authorized before §524B enforcement

Learn how Parasoft automates IEC 62304 compliance testing →

Cybersecurity Evidence

Powered by SBOMator™

Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.

Cyber Score60/100
SBOM Evidence⚠ Not mentioned in summary
Cyber Risk Assessment✓ Detected in Summary
Postmarket Plan✓ Detected in Summary
§524B ApplicableNo

Supply Chain BOM Evidence

Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.

SBOMSoftware Bill of Materials
- Not detected
ML-BOMMachine Learning Bill of Materials(algorithm)
✓ Detected
SaaSBOMSoftware-as-a-Service Bill of Materials(remote)
✓ Detected
HBOMHardware Bill of Materials(hardware, camera)
✓ Detected
CBOMCryptography Bill of Materials(encryption)
✓ Detected
VDR/VEXVulnerability Disclosure Report / Vulnerability Exploitability eXchange
- Not detected
OBOMOperations Bill of Materials(configuration, deployment, environment, operational)
✓ Detected

Analysis:

• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.

• Evidence of ML-BOM, SaaSBOM, HBOM, CBOM, OBOM detected in AI-generated device summary.

• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.

• Not detected in AI-generated device summary: SBOM, VDR/VEX. These may be present in the full FDA submission.

Preparing a similar submission?

ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.

Assess Your Readiness →Or contact ESL directly
Oxehealth Vital Signs - Oxehealth Limited | ESL FDA AI Device Intelligence